Expression of MMP‐7 and MT1‐MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis

Vicente, Juan Carlos de; Lequerica-Fernández, Paloma; Santamarı́a, Javier Gutiérrez; Fresno, Manuel

doi:10.1111/j.1600-0714.2007.00546.x

Cited by 63 publications

(59 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, clinicopathological variables and tumour-specific molecular markers that can identify patients with the highest risk of local recurrence have yet to be defined. 16,[18][19][20][21][22][23][42][43][44][45][46][47][48][49] Vimentin, a mesenchymal cell marker, associates with components of the cytoskeleton and membrane adhesions. Studies of human epithelial carcinomas, such as breast cancer, hepatocellular carcinoma, colon carcinoma, and prostatic adenocarcinoma, have shown that vimentin expression can be correlated with tumour invasion and a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Upregulation of vimentin and aberrant expression of E-cadherin/β-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome

et al. 2010

View full text Add to dashboard Cite

Oral squamous cell carcinoma is a challenging oncology problem. A reliable biomarker for metastasis or high-risk prognosis in oral cancer patients remains undefined. Using quantitative immunohistochemistry, we examined the expression of vimentin, E-cadherin, and b-catenin in 83 oral squamous cell carcinoma patients, and the relationships between the expression of these markers and specific clinicopathological features were analysed. The high expression of vimentin was observed in 23 of 43 (53%) tumours from patients who eventually developed a recurrent tumour and was associated with recurrence and death (Po0.001 and o0.001, respectively). The decreased expression of E-cadherin was observed in 36 of 43 (84%) tumours from patients who eventually developed a recurrent tumour and was also associated with recurrence and death (Po0.001 and o0.001, respectively). Although no correlation between b-catenin expression in whole-tumour sections and clinicopathological features was observed, decreased b-catenin expression at the tumour invasive front was closely associated with recurrence and death (P ¼ 0.002 and 0.002, respectively). The expression of vimentin and that of E-cadherin were associated with survival and were independent prognostic factors in univariate and multivariate analyses. Our data show that the overexpression of vimentin was closely associated with recurrence and death in oral squamous cell carcinoma patients. The combination of the upregulation of vimentin and aberrant expression of E-cadherin/b-catenin complexes at the tumour invasive front may provide a useful prognostic marker in oral squamous cell carcinoma. Modern Pathology (2010) 23, 213-224; doi:10.1038/modpathol.2009 published online 13 November 2009 Keywords: vimentin; oral squamous cell carcinoma; immunohistochemistry Oral cancer is the sixth most frequently occurring cancer worldwide, accounting for 3-5% of all malignancies in both sexes.1,2 Over 90% of all oral carcinomas are classified as oral squamous cell carcinoma, which remains a challenging oncology problem.3 Although early-stage oral squamous cell carcinoma can be treated or cured, the prognosis for advanced oral squamous cell carcinoma (stage III and IV) is poor. The treatment of oral squamous cell carcinoma is usually based on surgery or radiation, with or without concomitant chemotherapy. Despite these advanced therapeutic strategies, the 5-year survival rate of oral squamous cell carcinoma (B50%) has not increased over the past four decades.3-5 Local or regional relapse and cervical lymph node metastasis are the most prevalent

show abstract

Section: Discussionmentioning

confidence: 99%

Upregulation of vimentin and aberrant expression of E-cadherin/β-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome

et al. 2010

View full text Add to dashboard Cite

show abstract

“…It is in contrast to the Western literature, in which the tongue and mouth floor are the main sites. 22,25 In Taiwan, only 5-7% of oral cancer are graded as poorly differentiated type. 24,25 In our unpublished observation (H-C Chuang, unpublished observation), 1 of 118 documented patients (o1%) with buccal squamous cell carcinoma in our hospital is graded as poorly differentiated type.…”

Section: Discussionmentioning

confidence: 99%

“…18 However, the contribution of active MMP-7 vs MMP-7 in the progression of oral cancer has not been determined. [19][20][21][22][23] In the present study, we used tissue microarray together with immunohistochemistry and western blotting to analyze the expression of active MMP-7 in buccal squamous cell carcinoma and in normal tissues from the same patients and correlated these findings with clinicopathological features of buccal squamous cell carcinoma.…”

mentioning

confidence: 99%

Active matrix metalloproteinase-7 is associated with invasion in buccal squamous cell carcinoma

Chuang

Huang

et al. 2008

Modern Pathology

View full text Add to dashboard Cite

Protein microarrays have shown that matrix metalloproteinase-7 is upregulated in head and neck squamous cell carcinomas, but its role in local tissue invasion is still uncertain. We investigated the expression of active matrix metalloproteinase-7, using tissue microarray, immunohistochemistry, and western blotting, in oral tissues from 24 patients with buccal squamous cell carcinoma, and correlated the findings with clinicopathological features. Normal buccal tissue samples from the same patients, obtained at sites at least 1 cm from tumor tissue, served as normal controls. Total matrix metalloproteinase-7 was detected on western blots in 9 of 15 (60%) tumor tissue samples and in 2 of 15 (13%) normal mucosal samples; this difference was significant (P ¼ 0.008). Moreover, the active matrix metalloproteinase-7 was expressed only in eight of the nine (89%) tumor samples that expressed matrix metalloproteinase-7, and in none of the normal tissue samples, regardless of the expression status of the pro-matrix metalloproteinase-7. Immunostaining of matrix metalloproteinase-7 was observed histologically in both tumor and nonneoplastic epithelium, but immunostaining of active matrix metalloproteinase-7 was present only in tumor nests. Expression of active matrix metalloproteinase-7 was associated with larger tumor size (P ¼ 0.022) and was significantly higher in buccal squamous cell carcinoma with adjacent skin or bone invasion (P ¼ 0.036). In conclusion, active matrix metalloproteinase-7 expression was associated with more aggressive buccal squamous cell carcinomas.

show abstract

“…4,13,14,20,21 For treatment of cancers, the development of highly selective and specific MT1-MMP-inhibitors has been an important but rather demanding goal. The use of a limited spectrum inhibitor against the activities of gelatinases and MT1-MMP in the treatment of lung carcinoma has been shown to be promising.…”

Section: Discussionmentioning

confidence: 99%

A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth

Suojanen

Salo²,

Koivunen³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

Expression of MMP‐7 and MT1‐MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis

Cited by 63 publications

References 38 publications

Upregulation of vimentin and aberrant expression of E-cadherin/β-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome

Upregulation of vimentin and aberrant expression of E-cadherin/β-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome

Active matrix metalloproteinase-7 is associated with invasion in buccal squamous cell carcinoma

A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth

Contact Info

Product

Resources

About